PrIME Biologics
Plasma fractionation technology for high-yield therapeutic proteins
About PrIME Biologics
PrIME Biologics, founded in Singapore in 2010, specialized in plasma fractionation to produce therapeutic plasma products. The company's core technology, known as PrIME+, utilized a proprietary membrane-based system combined with GE Healthcare's chromatography to separate proteins from human blood plasma. This method was designed to achieve high yields and purity while ensuring the safety of the final products by removing contaminants like viruses and bacteria.
The company's primary market was Asia's therapeutic plasma products sector, an industry valued at over $1 billion at the time. PrIME Biologics aimed to address the demand for plasma-derived medicines, which are essential for treating a range of rare, chronic, and genetic diseases. The business model centered on establishing and commissioning a plasma fractionation facility in Singapore to manufacture these products. The company is now listed as deadpooled.
In October 2014, PrIME Biologics secured $12.5 million in a Series A funding round led by Xeraya Capital. Other investors included JP Asia Prime Capital and several angel investors. Records also show the company was acquired by Memphasys in the same year.
Source: Dealroom company dataNews
Open roles
PrIME Biologics in the Singapore ecosystem
The PrIME Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Xeraya Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PrIME Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PrIME Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


